BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary efficacy endpoint, showcasing a reduction in blood ...

In Phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms compared to placebo from baseline to ...

the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival ...

Roche said a trial for its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint in showing additional benefit in slowing disability progression with a higher dose. The Swiss ...

has not met its primary endpoint. Results from the company’s ongoing multi-centre, randomised, double-blind Musette trial (NCT04544436) found that Ocrevus failed to show additional benefit in ...

Squibb announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy as an ...

Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...

In the main trial, BP fell by 30.2±18.5/16.6±10.1 ... which was one of the primary endpoint components. For the overall primary endpoint, there was a 13% overall relative risk reduction for ...